ARCHIVES

Velcade Plus Dexamethasone Provides 20% Response In First-Line Treatment

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | December 29, 2006

Download PDF Visit The Full Archive

Related Articles

FDA, Genentech Agree On Framework for Avastin Hearing June 28-29

April 8, 2011

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014

In Brief: Coalition Dinner Celebrates NCI’s 50th Anniversary, Honors Lasker, Three Ex-Senators

September 18, 1987

ACS Awards Grants Totaling $31.3 Million

January 25, 1985

Letters to the Editor: Burzynski: Reviewers Sought To Discredit Antineoplaston Therapy

October 30, 1998

ASCO to Present 2013 Special Awards at Annual Meeting

May 31, 2013